Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-22, Stock:NVS, The news for the past five days is as follows:
2018-02-14: NEWS1: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS2: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS3: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS4: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS5: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS6: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS7: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS8: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS9: IIROC Trade Resumption - NVS.NEWS10: IIROC Trade Resumption - NVS.NEWS11: The Swiss Stock Market Regained Some Lost Ground.NEWS12: The Swiss Stock Market Regained Some Lost Ground.NEWS13: Generic Drugmakers to Dump as Teva's Woes Continue in 2018.NEWS14: Generic Drugmakers to Dump as Teva's Woes Continue in 2018.
2018-02-15: NEWS1: Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales.NEWS2: Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales.NEWS3: VEA, NSRGY, NVS, TM: ETF Inflow Alert.NEWS4: VEA, NSRGY, NVS, TM: ETF Inflow Alert.NEWS5: Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva.NEWS6: Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva.NEWS7: 3 Tough Questions for Amgen.NEWS8: 3 Tough Questions for Amgen.NEWS9: Keytruda: Merck’s Largest Revenue Contributor in 4Q17.NEWS10: 3 Tough Questions for Amgen.NEWS11: 3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate.NEWS12: 3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate.NEWS13: The Swiss Stock Market Inched Higher As NestlÃ© Weighs.NEWS14: The Swiss Stock Market Inched Higher As NestlÃ© Weighs.NEWS15: Nestle FY Profit Down;to Explore Strategic Options For Its Gerber Life Insurance.NEWS16: Nestle FY Profit Down;to Explore Strategic Options For Its Gerber Life Insurance.NEWS17: Roche's Rituxan Gets Priority Review for Label Expansion.NEWS18: Roche's Rituxan Gets Priority Review for Label Expansion.
2018-02-16: NEWS1: GlaxoSmithKline’s Revenues in 4Q17 Rose 1% Year-over-Year.NEWS2: How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients.NEWS3: Novartis’s Cosentyx May Emerge as a Leading Psoriasis Drug.NEWS4: Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles.NEWS5: Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017.NEWS6: Novartis readies to auction U.S. generic pills business - sources.NEWS7: Merck’s Human Vaccines Business in 4Q17.NEWS8: Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion.NEWS9: Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion.NEWS10: How Did Pfizer’s Legacy Established Products Segment Perform in 2017?.NEWS11: The Swiss Stock Market Extends Recovery And Finishes Week With A Gain.NEWS12: The Swiss Stock Market Extends Recovery And Finishes Week With A Gain.
2018-02-20: NEWS1: Novartis Plans to Launch RTH258 in 2019 to Treat nAMD.NEWS2: Wedbush: Restorbio's Therapy For Aging-Related Diseases Has Best-In-Class Potential.NEWS3: Incyte (INCY) Q4 2017 Earnings Conference Call Transcript.NEWS4: Novartis Seeks to Acquire Advanced Accelerator Applications.NEWS5: Novartis Psoriasis Drug Cosentyx Positive in SCALP Study.NEWS6: Novartis Psoriasis Drug Cosentyx Positive in SCALP Study.NEWS7: GlaxoSmithKline’s Vaccines Business in 4Q17.NEWS8: Promacta and Jakavi May Boost Novartis’s Oncology Segment Revenues.NEWS9: Novartis Psoriasis Drug Cosentyx Positive in SCALP Study.NEWS10: Today’s Research Reports on Trending Tickers: UnitedHealth Group and Novartis.NEWS11: GlaxoSmithKline’s Global Pharmaceuticals Business in 4Q17.NEWS12: Kisqali: Therapy for Advanced Breast Cancer in Premenopausal Women.NEWS13: The Swiss Stock Market Climbed On Strength Of Financials.NEWS14: The Swiss Stock Market Climbed On Strength Of Financials.
2018-02-21: NEWS1: Is Amgen Inc. a Buy?.NEWS2: Is Amgen Inc. a Buy?.NEWS3: Teva's Problems Continue to Mount With No Relief in Sight.NEWS4: Teva's Problems Continue to Mount With No Relief in Sight.NEWS5: ACZ885: A Robust Treatment Option for Reducing Cardiovascular Risk?.NEWS6: Analysts’ Recommendations for GlaxoSmithKline after 4Q17 Earnings.NEWS7: Novartis Plans to Expand its Multiple Sclerosis Portfolio in 2018.NEWS8: How Did JNJ’s Vision Care Segment Perform in 4Q17 and 2017?.NEWS9: Novartis Expects FDA and EMA Approvals for Aimovig in 2018.NEWS10: The Swiss Stock Market Inched Higher As Heavyweights Underperform.NEWS11: The Swiss Stock Market Inched Higher As Heavyweights Underperform.NEWS12: [$$] Novartis CEO Steers Drug Maker Back to R&D.NEWS13: Novartis Bribery Case in Greece Threatens to Bolster Populists.

Answer: Rise